Emerging evidence has demonstrated the alteration of components of several signaling pathways, such as epidermal growth factor receptor (EGFR) [2, 3], PI3K/AKT [4, 5], p53 [6, 7], p16INK4/cyclin D1/Rb pathways [8, 9], in lung cancer. The gene discussed is EGFR; the disease is lung cancer.